Latest Stocks: ValuEngine Upgrades Alnylam Pharmaceuticals, Inc. (ALNY) to Sell

Latest Stocks: ValuEngine Upgrades Alnylam Pharmaceuticals, Inc. (ALNY) to Sell

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) was upgraded by equities research analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a research note issued to investors on Friday.

ALNY has been the topic of several other research reports. Vetr lowered shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $46.77 target price on the stock. in a report on Monday, February 6th. Credit Suisse Group AG lowered shares of Alnylam Pharmaceuticals to a “hold” rating and set a $50.00 target price on the stock. in a report on Monday, March 20th. JMP Securities set a $69.00 target price on shares of Alnylam Pharmaceuticals and gave the company a “buy” rating in a report on Friday, February 3rd. Ladenburg Thalmann Financial Services initiated coverage on shares of Alnylam Pharmaceuticals in a report on Thursday, February 2nd. They set a “buy” rating and a $75.00 target price on the stock. Finally, Needham & Company LLC restated a “buy” rating and set a $68.00 target price (down previously from $98.00) on shares of Alnylam Pharmaceuticals in a report on Thursday, February 9th. Two analysts have rated the stock with a sell rating, six have issued a hold rating and twelve have assigned a buy rating to the company’s stock. Alnylam Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $70.50.

Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) opened at 69.93 on Friday. The stock has a 50 day moving average price of $60.18 and a 200 day moving average price of $49.28. Alnylam Pharmaceuticals has a 52 week low of $31.38 and a 52 week high of $80.11. The firm’s market capitalization is $6.03 billion.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Friday, May 5th. The biopharmaceutical company reported ($1.25) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.22) by $0.03. The business had revenue of $19 million for the quarter, compared to analyst estimates of $22.91 million. Alnylam Pharmaceuticals had a negative net margin of 869.63% and a negative return on equity of 37.25%. The business’s revenue was up 160.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($1.21) EPS. Equities analysts forecast that Alnylam Pharmaceuticals will post ($5.31) earnings per share for the current fiscal year.

In related news, major shareholder Sanofi bought 297,501 shares of the company’s stock in a transaction dated Wednesday, May 31st. The stock was bought at an average price of $71.87 per share, with a total value of $21,381,396.87. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, VP Michael Mason sold 9,375 shares of the business’s stock in a transaction dated Tuesday, May 16th. The stock was sold at an average price of $70.00, for a total transaction of $656,250.00. Following the completion of the sale, the vice president now directly owns 5,625 shares of the company’s stock, valued at approximately $393,750. The disclosure for this sale can be found here. Insiders sold a total of 64,125 shares of company stock valued at $4,325,000 in the last three months. Insiders own 4.00% of the company’s stock. Several large investors have recently made changes to their positions in the stock. FMR LLC increased its stake in shares of Alnylam Pharmaceuticals by 0.3% in the first quarter. FMR LLC now owns 12,907,883 shares of the biopharmaceutical company’s stock worth $661,530,000 after buying an additional 35,803 shares in the last quarter. Wellington Management Group LLP increased its stake in shares of Alnylam Pharmaceuticals by 0.3% in the first quarter. Wellington Management Group LLP now owns 12,041,179 shares of the biopharmaceutical company’s stock worth $617,111,000 after buying an additional 31,208 shares in the last quarter. Dodge & Cox acquired a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth $344,633,000. Vanguard Group Inc. increased its stake in shares of Alnylam Pharmaceuticals by 3.7% in the first quarter. Vanguard Group Inc. now owns 5,660,213 shares of the biopharmaceutical company’s stock worth $290,086,000 after buying an additional 200,890 shares in the last quarter. Finally, BlackRock Inc. increased its stake in shares of Alnylam Pharmaceuticals by 34,755.2% in the first quarter. BlackRock Inc. now owns 4,746,234 shares of the biopharmaceutical company’s stock worth $243,242,000 after buying an additional 4,732,617 shares in the last quarter. 88.70% of the stock is owned by institutional investors and hedge funds.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Related posts

Leave a Comment